Glenmark receives FDA approval for lidocaine ointment

The Food and Drug Administration recently approved India-based Glenmark Pharmaceutical’s lidocaine ointment.

Advertisement

The medication reduces itching and pain associated with skin conditions like scrapes, minor burns, bug bites and eczema.

Lidocaine is a generic version of Britain-based AstraZeneca’s Xylocaine ointment. Xylocaine reported annual sales of about $373 million for the 12-month period ending in July, according to data from IMS Health.

Glenmark’s U.S. portfolio includes 109 products. The company has 62 drug applications pending approval from the FDA.

More articles on supply chain:

5 myths about the EpiPen controversy
4 quotes from supply chain leaders on improving physician engagement
5 ways Mylan continues to dominate the epinephrine market

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

  • Abbott has launched an updated version of its Oncodetect blood test, which helps clinicians determine whether cancer remains in patients…

  • Becker’s asked supply chain leaders: If you had an extra $1 million for your supply chain budget, where would it…

  • As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

Advertisement

Comments are closed.